Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IrinoGem with Radiation for Locally Advanced Pancreatic Cancer
NCT00192712Phase 3Completed
- Sponsor
- Rambam Health Care Campus
- Start
- Nov 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of irinotecan in pancreatic cancer (PC), sponsored by Rambam Health Care Campus. Primary endpoint: Time to treatment failure. Started Nov 2002; status: completed.
02
Drugs
irinotecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00192712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00192712.